| Patent application number | Description | Published |
|---|
| 20080214528 | ANTI-INFECTIVE AGENTS - The present invention provides HCV polymerase inhibiting compounds having the formula (I): | 09-04-2008 |
| 20100120753 | Anti-Infective Agents - The present invention provides HCV polymerase inhibiting compounds having the formula (I): | 05-13-2010 |
| 20100144608 | Macrocyclic hepatitis C serine protease inhibitors - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 06-10-2010 |
| 20100168384 | ANTI-VIRAL COMPOUNDS - Compounds capable of inhibiting replication of the hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 07-01-2010 |
| 20100249181 | HIV Protease Inhibiting Compounds - A compound of the formula | 09-30-2010 |
| 20100261731 | Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1 Substrate - The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir. | 10-14-2010 |
| 20100280248 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS - Novel compounds of formula 1 | 11-04-2010 |
| 20100286032 | PRODRUGS OF HIV PROTEASE INHIBITORS - A compound of the formula | 11-11-2010 |
| 20110003827 | HIV protease inhibiting compounds - A compound of the formula | 01-06-2011 |
| 20110091423 | COMPOSITIONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV - The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof. | 04-21-2011 |
